Vaccine experts urge more inclusivity in clinical trials
The recently approved RSV vaccines have been celebrated as key public health tools, but some vaccine experts lamented that certain populations were largely left out of the clinical trials.
The recently approved RSV vaccines have been celebrated as key public health tools, but some vaccine experts have lamented one aspect of the trials that led to their approval — namely, that older adults were largely left out of them.
Among adults, RSV poses the biggest threat to the oldest seniors and people with certain preexisting health conditions. But the trials for the vaccines, which have been approved for adults 60 and older, included few participants 80 and older. People who are immunocompromised and those who live in nursing homes were also not included.
What's Your Reaction?
